Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1005

1.

M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R.

J Mol Neurosci. 2003;20(3):349-56. Review.

PMID:
14501019
2.

AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.

Fisher A, Brandeis R, Bar-Ner RH, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53.

PMID:
12212772
3.

Impact of muscarinic agonists for successful therapy of Alzheimer's disease.

Fisher A, Brandeis R, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z.

J Neural Transm Suppl. 2002;(62):189-202. Review.

PMID:
12456063
4.

Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.

Fisher A.

Jpn J Pharmacol. 2000 Oct;84(2):101-12. Review.

5.

M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives.

Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z.

Ann N Y Acad Sci. 2000;920:315-20.

PMID:
11193170
6.

M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.

Fisher A.

Curr Alzheimer Res. 2007 Dec;4(5):577-80. Review.

PMID:
18220527
7.

M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.

Fisher A.

Neurodegener Dis. 2008;5(3-4):237-40. doi: 10.1159/000113712. Epub 2008 Mar 6. Review.

PMID:
18322400
8.

Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists.

Beach TG, Walker DG, Potter PE, Sue LI, Fisher A.

Brain Res. 2001 Jun 29;905(1-2):220-3.

PMID:
11423097
9.

M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.

Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD.

Ann N Y Acad Sci. 1996 Jan 17;777:189-96. Review.

PMID:
8624083
10.

[Alzheimer disease: cellular and molecular aspects].

Octave JN.

Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1. French.

PMID:
16768248
11.
12.

M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM.

Neuron. 2006 Mar 2;49(5):671-82.

13.

Disease-modifying therapies in Alzheimer's disease: how far have we come?

Hüll M, Berger M, Heneka M.

Drugs. 2006;66(16):2075-93. Review.

PMID:
17112302
14.

The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease.

Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH.

Ann Neurol. 2000 Dec;48(6):913-8.

PMID:
11117548
15.

[Therapy of Alzheimer disease].

Kovács T.

Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Review. Hungarian.

16.

Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice.

Lee JW, Lee YK, Ban JO, Ha TY, Yun YP, Han SB, Oh KW, Hong JT.

J Nutr. 2009 Oct;139(10):1987-93. doi: 10.3945/jn.109.109785. Epub 2009 Aug 5.

17.

(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.

Fisher A, Brandeis R, Karton I, Pittel Z, Gurwitz D, Haring R, Sapir M, Levy A, Heldman E.

J Pharmacol Exp Ther. 1991 Apr;257(1):392-403.

PMID:
2019998
18.

Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.

Chandra JN, Malviya M, Sadashiva CT, Subhash MN, Rangappa KS.

Neurochem Int. 2008 Feb;52(3):376-83. Epub 2007 Jul 10.

PMID:
17719699
19.

Progress in medicinal chemistry of novel selective muscarinic agonists.

Fisher A, Karton Y, Heldman E, Gurwitz D, Haring R, Meshulam H, Brandeis R, Pittel Z, Segall Y, Marciano D, et al.

Drug Des Discov. 1993;9(3-4):221-35. Review.

PMID:
8400004
20.

Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease.

Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, Müller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM.

Amyloid. 2003 Mar;10(1):1-6.

PMID:
12762134

Supplemental Content

Support Center